탭메뉴
| 번호 | 구분 | 제목 |
|---|---|---|
| 313 | (국외)SCI | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| 312 | (국외)SCI | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| 311 | (국외)SCI | Systemic Delivery of a STING Agonist-Loaded PositivelyCharged Liposome Selectively Targets Tumor ImmuneMicroenvironment and Suppresses Tumor Angiogenesis |
| 310 | (국외)SCI | Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial |
| 309 | (국외)SCI | Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma |
| 308 | (국외)SCI | Multifunctional porous microspheres encapsulating oncolytic bacterial spores and their potential for cancer immunotherapy |
| 307 | (국외)SCI | ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer |
| 306 | (국외)SCI | ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer |
| 305 | (국외)SCI | High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma?Reply |
| 304 | (국외)SCI | High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma?Reply |
1
Copyright ⓒ chamc, All rights reserved.
